Last reviewed · How we verify
Clozaril — Competitive Intelligence Brief
phase 1
Aldehyde oxidase, UDP-glucuronosyltransferase 1-4, 5-hydroxytryptamine receptor 1E
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
Clozaril (Clozaril) — Dong Wha Pharmaceutical Co. Ltd..
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Clozaril TARGET | Clozaril | Dong Wha Pharmaceutical Co. Ltd. | phase 1 | Aldehyde oxidase, UDP-glucuronosyltransferase 1-4, 5-hydroxytryptamine receptor 1E | ||
| Fazaclo | Fazaclo | Manhattan Psychiatric Center | marketed | Aldehyde oxidase, UDP-glucuronosyltransferase 1-4, 5-hydroxytryptamine receptor 1E |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Clozaril — Competitive Intelligence Brief. https://druglandscape.com/ci/clozaril. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing